New Pooling Strategy Increases Efficiency and Reduces Cost of COVID-19 PCR Tests
|
By LabMedica International staff writers Posted on 31 Aug 2020 |

Image: The CDC 2019 Novel Coronavirus (2019-nCoV) Real-Time Reverse Transcriptase (RT)–PCR Diagnostic Panel detects the SARS-CoV-2 virus in upper and lower respiratory specimens. The new P-BEST approach provides both an eight-fold improvement in testing efficiency as well as an eight-fold reduction in cost of PCR testing (Photo courtesy of Center for Disease Control and Prevention)
A new way of manipulating samples for COVID-19 testing of asymptomatic and symptomatic individuals provides both an eight-fold increase in testing efficiency, as well as an eight-fold reduction in test costs.
Recent reports have suggested that10-30% of SARS-CoV-2 (COVID-19) infected patients are asymptomatic and that significant viral shedding may occur prior to symptom onset. Therefore, there is an urgent need to increase diagnostic testing capabilities to prevent disease spread. A major bottleneck of managing the COVID-19 pandemic in many countries is diagnostic testing, which is primarily performed on symptomatic patients, due to limited laboratory capabilities as well as limited access to genome-extraction and PCR (Polymerase Chain Reaction) reagents.
To break this bottleneck, investigators at Ben-Gurion University of the Negev (Beer Sheva, Israel) developed P-BEST, a method for Pooling-Based Efficient SARS-CoV-2 Testing, which identifies all positive subjects within a large set of samples using a single round of testing.
In the P-BEST approach, each individual’s sample is assigned into multiple pools using a combinatorial pooling strategy based on compressed sensing designed for maximizing carrier detection. In the pilot study, the investigators pooled sets of 384 samples into 48 pools, which provided both an eight-fold increase in testing efficiency, as well as an eight-fold reduction in test costs.
Results revealed that the P-BEST method successfully identified up to five positive carriers within sets of 384 samples. P-BEST could be configured based on the carrier rate of a given population. Thus, if the carrier rate was below 1.3%, the method provided both an eight-fold improvement in testing efficiency as well as an eight-fold reduction in test costs.
"Approximately 10-30% of COVID-19 infected patients are asymptomatic and significant viral spread can occur days before symptom onset," said contributing author Dr. Angel Porgador, deputy vice-president of research and development at Ben Gurion University of the Negev. "Until there is a vaccine, there will be an urgent need to increase diagnostic testing capabilities to allow for screening of asymptomatic and pre-symptomatic populations. This new single stage diagnostic test will help prevent the spread of the disease by identifying these patients sooner and at a lower cost using significantly fewer tests."
The P-BEST method was described in the August 21, 2020, online edition of the journal Science Advances.
Related Links:
Ben-Gurion University of the Negev
Recent reports have suggested that10-30% of SARS-CoV-2 (COVID-19) infected patients are asymptomatic and that significant viral shedding may occur prior to symptom onset. Therefore, there is an urgent need to increase diagnostic testing capabilities to prevent disease spread. A major bottleneck of managing the COVID-19 pandemic in many countries is diagnostic testing, which is primarily performed on symptomatic patients, due to limited laboratory capabilities as well as limited access to genome-extraction and PCR (Polymerase Chain Reaction) reagents.
To break this bottleneck, investigators at Ben-Gurion University of the Negev (Beer Sheva, Israel) developed P-BEST, a method for Pooling-Based Efficient SARS-CoV-2 Testing, which identifies all positive subjects within a large set of samples using a single round of testing.
In the P-BEST approach, each individual’s sample is assigned into multiple pools using a combinatorial pooling strategy based on compressed sensing designed for maximizing carrier detection. In the pilot study, the investigators pooled sets of 384 samples into 48 pools, which provided both an eight-fold increase in testing efficiency, as well as an eight-fold reduction in test costs.
Results revealed that the P-BEST method successfully identified up to five positive carriers within sets of 384 samples. P-BEST could be configured based on the carrier rate of a given population. Thus, if the carrier rate was below 1.3%, the method provided both an eight-fold improvement in testing efficiency as well as an eight-fold reduction in test costs.
"Approximately 10-30% of COVID-19 infected patients are asymptomatic and significant viral spread can occur days before symptom onset," said contributing author Dr. Angel Porgador, deputy vice-president of research and development at Ben Gurion University of the Negev. "Until there is a vaccine, there will be an urgent need to increase diagnostic testing capabilities to allow for screening of asymptomatic and pre-symptomatic populations. This new single stage diagnostic test will help prevent the spread of the disease by identifying these patients sooner and at a lower cost using significantly fewer tests."
The P-BEST method was described in the August 21, 2020, online edition of the journal Science Advances.
Related Links:
Ben-Gurion University of the Negev
Latest Technology News
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
- Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Channels
Clinical Chemistry
view channel
Urine-Based Nanosensor Tracks Lung Cancer and Fibrosis Noninvasively
Lung cancer remains difficult to monitor for early progression and treatment resistance, while pulmonary fibrosis continues to pose major challenges for early diagnosis. Clinicians need repeatable, noninvasive... Read more
Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection
Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Routine TB Screening Test May Reveal Immune Aging and Mortality Risk
Immune aging is associated with weaker responses to vaccination, greater risks of infection, and higher levels of inflammation. Leveraging routinely ordered laboratory tests to quantify that responsiveness... Read more
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read moreMicrobiology
view channel
Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
Limited access to general practitioners and pathology services can delay diagnosis and monitoring for people in regional and remote communities. Rapid, on-the-spot testing can shorten turnaround times... Read more
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read moreIndustry
view channel
Partnership Aims to Bring Risk-Guided CKD Care to Health Systems
Chronic kidney disease (CKD) places a substantial clinical and financial burden on the United States. As health systems face growing pressure to detect risk earlier and manage progression proactively,... Read more








